E. Gabriela Chiorean

Also affiliated with Fred Hutch Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 25 papers. Top paper: “Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine”.

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

New England Journal of Medicine(2013)10.1056/nejmoa1304369

N/A

1.3DataRank · unranked

6585 citations

Thomas Ervin, Francis P. Arena, E. Gabriela Chiorean, Jeffrey Infante, Fruzsina Molnar-Gabor +26 more

SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

Journal of Clinical Oncology(2024)10.1200/jco-24-01383

N/A

1.1DataRank · unranked

51 citations

Gentry Teng King, Sarah Colby, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff +17 more

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1047

N/A

0.784DataRank · unranked

185 citations

Courtney B. Betts, Rosemarie Mick, Shamilene Sivagnanam, David L. Bajor, Daniel A. Laheru +24 more

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial

Journal of Clinical Oncology(2025)10.1200/jco-24-01710

N/A

0.458DataRank · unranked

9 citations

Katherine A. Guthrie, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman +15 more

APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps763

N/A

0.330DataRank · unranked

8 citations

Sung Chul Hong, Anup Kasi, Eileen M. O’Reilly, Shishir K. Maithel, Xin Yao +10 more

S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)

Future Oncology(2025)10.1080/14796694.2025.2485020

N/A

0.176DataRank · unranked

2 citations

Sarah Colby, Paul E. Oberstein, Dan G. Duda, Robin Park, Rajiv Agarwal +12 more

Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.419

N/A

0DataRank · unranked

2 citations

Mai T. Duong, Renee B. Chang, Yuqing Xue, Devora Delman, Ignacio Garrido‐Laguna +15 more

Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4131

N/A

0DataRank · unranked

0 citations

Mai T. Duong, Robert D. Boutin, Leon Lenchik, Jiyoon Kim, Namita Gandhi +11 more

Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps515

N/A

0DataRank · unranked

9 citations

Katherine A. Guthrie, Syed A. Ahmad, M. Kay Washington, Brian Hemendra Ramnaraign, Nitya Raj +8 more

SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4179

N/A

0DataRank · unranked

5 citations

Edward Mayerson, E. Gabriela Chiorean, Earle F. Burgess, Elizabeth M. Swisher, Carl M. Gay +9 more

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.lba490

N/A

0DataRank · unranked

99 citations

Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin +15 more

Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps447

N/A

0DataRank · unranked

13 citations

Katherine A. Guthrie, Michael J. Pishvaian, Andrew M. Lowy, E. Gabriela Chiorean, Mai T. Duong +3 more

A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.140

N/A

0DataRank · unranked

7 citations

Katherine A. Guthrie, Scott Kopetz, Benjamin Tan, Crystal S. Denlinger, Marwan Fakih +15 more

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4198

N/A

0DataRank · unranked

6 citations

Katherine A. Guthrie, Michael J. Pishvaian, Kim Anna Reiss, Andrew M. Lowy, Davendra Sohal +7 more

Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4202

N/A

0DataRank · unranked

3 citations

Sung Chul Hong, Anup Kasi, Eileen M. O’Reilly, Shishir K. Maithel, Xin Yao +10 more

P-228 Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107

Annals of Oncology(2023)10.1016/j.annonc.2023.04.284

N/A

0DataRank · unranked

2 citations

Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas B. Karasic, Zelan Hu +7 more

Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps784

N/A

0DataRank · unranked

1 citations

Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby +7 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

(2023)10.1158/1078-0432.c.6531176.v1

N/A

0DataRank · unranked

0 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1789

N/A

0DataRank · unranked

53 citations

Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia G. Jalikis, Michael J. Pishvaian +11 more

Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma

Gastroenterology(2024)10.1053/j.gastro.2024.01.013

N/A

0DataRank · unranked

18 citations

Sarah Colby, Ignacio Garrido‐Laguna, Yuqing Xue, Renee B. Chang, Devora Delman +14 more

HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2200

N/A

0DataRank · unranked

8 citations

Stephanie Dobersch, Ian M. Loveless, Annie N. Samraj, Gun Ho Jang, Miki Haraguchi +17 more

Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.732

N/A

0DataRank · unranked

1 citations

David B. Zhen, Marc R. Radke, Kelsey K. Baker, Andrew L. Coveler, Kit Man Wong +5 more

Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505

Cancer(2025)10.1002/cncr.35759

N/A

0DataRank · unranked

2 citations

Sarah Colby, Davendra Sohal, Katherine A. Guthrie, Lisa A. Kachnic, E. Gabriela Chiorean +6 more

SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4504

N/A

0DataRank · unranked

115 citations

Mai T. Duong, Syed A. Ahmad, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang‐Gillam +7 more